Grant
Opportunities
CDFAC Grant Application Summary
Advancing Translational Research in Mitochondrial Dysfunction
The CDFAC Grant supports innovative projects aimed at developing treatments and diagnostic tools for primary and secondary mitochondrial diseases. This program funds research with a strong translational focus, encouraging collaboration and novel approaches to address mitochondrial dysfunction.
Grant Funding Overview
- Funding: Applicants must specify their requested funding amount and justify how the funds will be utilized based on the project scope.
- Grant Duration:
- Standard: 12 months
- Extensions: Up to 24 months with justification
- Milestone-Based Fund Disbursement:
- 50% at project start
- 25% after 6-month progress review
- 25% upon final report submission
Application Process
Step 1: Full Proposal Submission
- Page Limit: 6 pages (excluding references & appendices)
- Budget: Justification required; no indirect costs allowed
- Proposal Must Include:
- Significance & relevance to mitochondrial dysfunction
- Innovation & feasibility
- Pathway to clinical application
- Ethical considerations
Step 2: Peer Review & Evaluation
Proposals will be evaluated by experts in mitochondrial research, clinical practice, and related fields.
Review Criteria & Weights:
- Scientific Merit (25%)
- Impact & Relevance (20%)
- Feasibility (25%)
- Innovation (20%)
- Collaboration & Technology Integration (10%)
- Ethical Considerations (10%)
Step 3: Final Funding Decision
- Scoring: 1 (Exceptional) – 7 (Very Poor)
- Top-ranked proposals will receive funding
- Appeals allowed only for procedural errors
Key Dates & Deadlines (TBD)
Stage | Deadline | Notification |
|---|---|---|
Full Proposal Submission | Accepting applications until September 5th | 6-8 weeks post-review |
Post-Award Requirements
- 6-Month Progress Report (scientific updates, budget review)
- Final 12-Month Report (impact, outcomes, next steps)
- Selected projects may present at the Annual Funding Event
Contact: Grants@countdownforacure.org for inquiries.